Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

19.02.2021 | short review | Ausgabe 1/2021 Open Access

memo - Magazine of European Medical Oncology 1/2021

Immunoglobulin light chain amyloidosis

Short tutorial in screening, early detection, risk assessment and response evaluation

memo - Magazine of European Medical Oncology > Ausgabe 1/2021
Hermine Agis, Maria T. Krauth
Wichtige Hinweise

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Immunoglobulin light chain (AL) amyloidosis is a rare and underdiagnosed life-threatening systemic disease, primarily caused by insoluble depositions of misfolded monoclonal light chains. The monoclonal light chain paraprotein originates from a small clonal B‑cell or a clonal plasma cell population. If left undetected the paraprotein can induce a number of complications based on organ damage. The most dangerous and life-threatening organ dysfunction emerges from cardiac involvement. Thus, patients overall survival depends on early detection. Establishing the correct diagnosis and clear characterization of the amyloid-forming protein, staging, risk assessment and treatment are crucial and depend on a highly experienced interdisciplinary, multiprofessional team.

Unsere Produktempfehlungen

Abo für kostenpflichtige Inhalte

Über diesen Artikel

Weitere Artikel der Ausgabe 1/2021

memo - Magazine of European Medical Oncology 1/2021 Zur Ausgabe